Abstract LB242: Discovery and characterization of BRSD-143, an orally bioavailable panKRAS inhibitor
Charles Y. Cho, Jacob R. Haling(Genomics Institute of the Novartis Research Foundation), Michael DiDonato, Hong Sae Jin, Danielle Roman(Novartis (Switzerland)), Xianzhong Liu, Guoxun Liu(Genomics Institute of the Novartis Research Foundation), Deborah Knee, David P. Kodack(Novartis (United States)), Vicki Zhou(Genomics Institute of the Novartis Research Foundation), Wendy Richmond, E S Kim, Darbi Witmer, Dean P. Phillips, Yvonne Wang(Yale University), Michael Shapiro, Brandon L. Taylor(Genomics Institute of the Novartis Research Foundation), Yelena Sarkisova(Genomics Institute of the Novartis Research Foundation), Cyrus Virata, David A. Ruddy(Novartis (Switzerland)), Michelle Piquet, Rita Das(Harvard University), Hong Yin, Qian Liu, Lilin Li(Tsinghua University), Todd Groessl, Jie Li(Nanjing University of Chinese Medicine), Yong Jia(Genomics Institute of the Novartis Research Foundation), Jun Liu(Longyan University), Yu Chen(Tulane University), Min Lu(South China Agricultural University), W. Perry Gordon, Dmitry Borkin, David H. Jones, Varunika Vivekanandan, Flavio Somanji, Miriam Coor, Dong Han, Agnes Vidal-Biggart, Phillip B. Alper
Cited by 0
Related Papers
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
|Nature Medicine|2015|1.4k
2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis
|Clinical Gastroenterology and Hepatology|2021|708
Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss
|Nature Medicine|2018|369
Lipase-catalyzed transesterification of rapeseed oils for biodiesel production with a novel organic solvent as the reaction medium
|Journal of Molecular Catalysis B Enzymatic|2006|360